1. Imugene (IMU) - PH's first child. B-Cell technology platform has been de-risked. Very undervalued at current MC. Drug supply deals with Merck KGaA, Pfizer and Merck & Co. Collaborations with Eureka Therapeutics and Celularity. The closest of the three to signing a deal with big pharma. World class management and SAB.
2. Chimeric Therapeutics (CHM) - Early stage. High risk. Has the potential to be bigger and better than IMU. World class management and SAB.
3. Radiopharm Theranostics (RAD) - Not invested and not interested. PH has enough of my $$$ invested in his companies...hahaha
1. Imugene (IMU) - PH's first child. B-Cell technology platform...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $26.18K | 1.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 736556 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1462067 | 5 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |